Multiple sclerosis (MS) is an autoimmune demyelinating and neurodegenerative disease of
the central nervous system, and the leading cause of nontraumatic neurological disability in …

Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous
system (CNS) where immunopathology is thought to be mediated by myelin-reactive CD4+ T …

Background Ofatumumab, a subcutaneous anti-CD20 monoclonal antibody, selectively
depletes B cells. Teriflunomide, an oral inhibitor of pyrimidine synthesis, reduces T-cell and …

Importance Accumulation of disability in multiple sclerosis may occur as relapse-associated
worsening (RAW) or steady progression independent of relapse activity (PIRA), with PIRA …

Importance Although highly effective disease-modifying therapies for multiple sclerosis (MS)
have been associated with an increased risk of infections vs injectable therapies interferon …

Maria was distraught after reading about the 'potential'epidemic, yet to happen, and the
horror stories on Facebook needing reassurance and certainty about what she should do …

In this study (trial registration: NCT02166021), we aimed to evaluate the optimal way of
administration, the safety and the clinical efficacy of mesenchymal stem cell (MSC) …

Background The safety and efficacy of ocrelizumab in primary progressive multiple sclerosis
were shown in the phase 3 ORATORIO trial. In this study, we assessed the effects of …

Central nervous system B cells have several potential roles in multiple sclerosis (MS):
secretors of proinflammatory cytokines and chemokines, presenters of autoantigens to T …

Early evaluation of treatment response and prediction of disease evolution are key issues in
the management of people with multiple sclerosis (MS). In the past 20 years, MRI has …